Loading...
Treatment of esophagogastric cancer has evolved with approval of immune checkpoint inhibitors to combine with first-line chemotherapy. The benefit of these agents may depend on expression of the target, PD-L1.
Investigators report results of KEYNOTE-590, an industry-sponsored, international, placebo-controlled, double-blind, phase 3 trial comparing chemotherapy with infusional 5-FU and cisplatin with or without the addition of pembrolizumab in advanced esophageal squamous cell carcinoma (SCC) or adenocarcinoma. Of 749 patients, 54% were from Asia, 73% had SCC, and 51% had PD-L1 combined positive scores (CPS) ≥10%.
The dual primary endpoints of improved overall survival (OS) in patients with SCC and CPS ≥10% and improved OS and progression-fre…